Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia.
Aims: To explore the incidence, severity, time course, and risk factors of clinically significant hyponatremia in desmopressin treatment for nocturia. Methods: Data from three multi-center phase 111 trials were pooled. Hyponatremia was categorised as borderline (134-130 mmol/L) or significant (= 65 years of age) with a baseline serum sodium concentration below normal range were at high risk (75%).